While minimal residual disease (MRD) has been a topic of research for at least a decade, right now it is more top of mind than ever before for people treating cancer, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
While minimal residual disease (MRD) has been a topic of research for at least a decade, right now it is more top of mind than ever before for people treating cancer, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Transcript
How is our understanding of MRD and what it means for treatment decisions evolving?
Minimal residual disease is a topic that is on everybody's lips these days. You cannot attend one single meeting without hearing about the minimal residual disease [MRD] testing in myeloma and other diseases, as well. I have worked on it for more than 10 years, and we worked on it in the laboratory. We have used flow cytometry-based, we have used PCR [polymerase chain reaction]-based, we have done next generation sequencing based, we have done proteomic-based [testing], and we also have started doing immuno-PET—based imaging for minimal residual disease.
All the data in multiple myeloma that has been generated from larger studies show that if you treat a newly diagnosed patient and he or she obtains him MRD negativity, that's probably the strongest prognostic factor for a long progression-free survival. And there is that even showing that it could be a prognostic factor associated with long overall survival. We published the first meta-analysis back in 2016, and there was a subsequent meta-analysis in 2017, using very similar data sets, plus some additional older data sets, as well. So, there are 2 meta-analyses in showing in myeloma that MRD is very important, prognostically.
There is not yet any study that has been published that's designed to use MRD for decision making, but there are several ongoing studies, we have at our center, as well, looking at the role of MRD as a decision tool to determine whether therapy could be increased in intensity or decreased or could you even use patients that are MRD negative for many years and use that MRD to determine whether patient potentially could even be stopped for therapy. So, those are studies that are ongoing, and it will be very interesting to see what the data shows.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More